A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Phase ⅡStudy to Evaluate the Efficacy and Safety of HRS-7535 in Obese Subjects
Latest Information Update: 16 Apr 2025
At a glance
- Drugs HRS-7535 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Shandong Suncadia Medicine
Most Recent Events
- 09 Apr 2025 Status changed from not yet recruiting to completed.
- 13 Feb 2024 New trial record